NGNE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Neurogene Inc (NGNE) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows strong potential for growth based on technical indicators, analyst ratings, and the company's focus on a promising therapeutic area. Despite insider selling and lack of revenue, the long-term upside potential outweighs the risks.
The stock is in a bullish trend with SMA_5 > SMA_20 > SMA_200. The MACD histogram is positive at 0.623, indicating bullish momentum, while RSI_6 at 68.162 is neutral. The pre-market price of $27.61 is above the pivot level of $24.272, with resistance levels at $28.061 and $30.402.
Canaccord's Buy rating with a $180 price target and projected peak sales of $2.2B for NGN-401 by
The company's focus on Rett syndrome, a large rare disease market, with potential U.S. and EU launches in 2028 and 2029 respectively.
Stock trend analysis shows an 80% chance of a 7.92% increase in the next week and 32.01% in the next month.
Insiders are selling, with a 262.18% increase in selling activity over the last month.
The company has no revenue and reported a net loss of $24.735M in Q4
No recent news or congress trading data to support immediate momentum.
The company reported a net loss of $24.735M in Q4 2025, though this is a 26.76% YoY improvement. EPS improved by 12% to -1.12, but gross margin dropped to 0%. The company remains pre-revenue.
Analysts are bullish on NGNE. Canaccord has a Buy rating with a revised price target of $180, down from $200, citing strong potential for NGN-401. LifeSci Capital also initiated coverage with an Outperform rating and a $50 price target. Analysts highlight the company's strong capitalization and long-term growth potential.
